NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development

Eugene Izumchenko(Ben-Gurion University of the Negev), Mahendra Singh(Fox Chase Cancer Center), Olga V. Plotnikova(Fox Chase Cancer Center), Nadezhda Tikhmyanova(Fox Chase Cancer Center), Joy L. Little(Fox Chase Cancer Center), Ilya G. Serebriiskii(Fox Chase Cancer Center), Sachiko Seo(The University of Tokyo), Mineo Kurokawa(The University of Tokyo), Brian L. Egleston(Fox Chase Cancer Center), Andres J. Klein–Szanto(Fox Chase Cancer Center), Elena N. Pugacheva(West Virginia University), Richard R. Hardy(Fox Chase Cancer Center), Marina Wolfson(Ben-Gurion University of the Negev), Denise C. Connolly(Fox Chase Cancer Center), Erica A. Golemis(Fox Chase Cancer Center)
Cancer Research
September 8, 2009
Cited by 154Open Access
Full Text

Abstract

In the past 3 years, altered expression of the HEF1/CAS-L/NEDD9 scaffolding protein has emerged as contributing to cancer metastasis in multiple cancer types. However, whereas some studies have identified elevated NEDD9 expression as prometastatic, other work has suggested a negative role in tumor progression. We here show that the Nedd9-null genetic background significantly limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model. Action of NEDD9 is tumor cell intrinsic, with immune cell infiltration, stroma, and angiogenesis unaffected. The majority of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9(-/-) mice are characterized by depressed activation of proteins including AKT, Src, FAK, and extracellular signal-regulated kinase, emphasizing an important role of NEDD9 as a scaffolding protein for these prooncogenic proteins. Analysis of cells derived from primary Nedd9(+/+) and Nedd9(-/-) tumors showed persistently reduced FAK activation, attachment, and migration, consistent with a role for NEDD9 activation of FAK in promoting tumor aggressiveness. This study provides the first in vivo evidence of a role for NEDD9 in breast cancer progression and suggests that NEDD9 expression may provide a biomarker for tumor aggressiveness.


Related Papers

No related papers found

Powered by citation graph analysis